Business Wire

Altasciences Continues Manufacturing Expansion in Philadelphia With Client‑Dedicated Building Project

Share

Altasciencesformulation, manufacturing, and analytical services facilities in Philadelphia, PA, are undergoing further expansion. Altasciences—an integrated CRO/CDMO offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies—is building client‑dedicated facilities for Alladapt Immunotherapeutics, Inc. (“Alladapt”), a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, with a scheduled completion time in 2023.

Having developed the formulation and manufacturing processes to meet all of Alladapt’s Phase I and II clinical trial needs, Altasciences has been contracted to continue the process with the construction of a new 53,000-square-foot building that will meet Alladapt’s Phase III and commercial requirements. Altasciences will manage all aspects of this project, including warehousing, release management, manufacturing, quality assurance, and finished product release. The new building will have additional client dedicated capacity that can be used for Phase I through to commercial manufacturing services.

We are pleased to continue supporting Alladapt in their important goal of developing a single therapeutic to address a wide range of mono- and multi-food allergies, and we look forward to fulfilling their Phase III and commercial requirements,” stated Ben Reed, General Manager, CDMO Services at Altasciences.

The training Altasciences provides their CDMO workforce is second to none, as each team member is well-equipped to optimize and complete our manufacturing projects. We are proud to partner with Altasciences to continue advancing the clinical development of our potentially best in-class oral immunotherapy candidate, ADP101,” said Ashley Dombkowski, Ph.D., Chief Executive Officer and co-founder at Alladapt.

About Altasciences

Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pharma Tech Holdings SA Obtains a Capital Commitment Agreement of CHF 30 million from Global Investor LDA Capital8.8.2022 10:50:00 CEST | Press release

Pharma Tech Holding SA (“PTH”) announced today it has secured a CHF 30 million investment to support its portfolio investments from LDA Capital Ltd, a global investment group with expertise in cross border transactions including the agriculture, Agri-tech, and CBD industries. Established in 2019, PTH is a Swiss based holding company, which invests into innovative businesses with high technological value and scalability potential, mainly in Switzerland and Europe, with a focus on the health-tech, Agri-tech, and functional food. This investment will allow PTH to mainly invest and support its portfolio company Blue Sky Swisse SA (“BSS”) a JV between PTH and listed company IGEA PHARMA NV (“Igea”), IGPH - ISIN NL0012768675. BSS focuses on the extraction of natural active principles from vegetable matrices, vegetable waste, and renewable sources to deliver B2B products under the form of CBD oil, Terpenes and Waxes. The factory located in Biasca, will be built to the state of art of extractio

Smile Hair Clinic Named 'Hair Transplant Clinic of the Year'8.8.2022 09:30:00 CEST | Press release

The Smile Hair Clinic took two awards in the ‘Highest Quality Hair Transplantation Clinic’, and the 'Hair Clinic of the Year' categories at the 13th Annual Quality of Magazine Klass Award Ceremony. Dr. Gokay Bilgin and Dr. Mehmet Erdoğan founded the Smile Hair Clinic in 2018 and have since overseen its successful and award-winning growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220808005053/en/ Smile Hair Clinic named 'Hair Transplant Clinic of the Year' (Graphic: Business Wire) Award Ceremony: https://www.youtube.com/watch?v=0TvUp2FxRII Accepting the award Dr. Bilgin said, "Our country holds an important position in medicine globally; patients from all over the world come to Turkey for treatment." Award winners Dr. Bilgin and Dr. Erdoğan have many years of experience in follicular unit extraction (FUE) techniques. Located on Istanbul’s Anatolian neighborhood of Ataşehir, the clinic has more than 100 trained personnel

Teckro Partners with Reforestation Non-profit “One Tree Planted”5.8.2022 15:04:00 CEST | Press release

Teckro, creator of the only digitally interconnected clinical trial platform for real-time decision-making at the point of patient care, today announced a partnership with One Tree Planted to support native reforestation in Ireland. Teckro will plant trees quarterly to celebrate new clinical research sites and studies live on the Teckro platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220805005165/en/ “Working with One Tree Planted aligns with Teckro’s ethos of making an impact in the world,” said Gary Hughes, co-founder and chief executive officer. “Digitally interconnected clinical trials are good for the environment with less paper and a reduced need for in-person monitoring visits. This partnership enables us to plant trees in recognition of the sustainable gains achieved with our platform.” Planting trees is one of the best ways to combat the damaging effects of climate change. Trees help clean the air we breath

SES to Participate in Upcoming Investor Conferences5.8.2022 13:45:00 CEST | Press release

SES AI Corporation (NYSE: SES), a global leader in the development and manufacturing of high-performance lithium-metal (Li-Metal) rechargeable batteries for electric vehicles (EVs) and other applications, today announced that management will participate and host one-on-one meetings at the following investor conferences. J.P. Morgan Auto Conference Date: August 9, 2022 Location: New York City Jefferies Industrials Conference Date: August 10, 2022 Location: New York City Baird Newly Public Company Virtual Access Day Date: August 17, 2022 Location: Virtual Piper Sandler Energy Transition Leaders Summit Date: August 18, 2022 Location: Aspen, CO Cowen Global Transportation & Sustainable Mobility Conference Date: September 8, 2022 Location: Virtual RBC Capital Markets Global Industrials Conference Date: September 12, 2022 Location: Las Vegas, NV About SES SES is a global leader in development and production of high-performance Li-Metal rechargeable batteries for electric vehicles (EVs) and o

Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 20225.8.2022 07:00:00 CEST | Press release

Regulatory News: Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the Shares) of Epizyme, Inc. (NASDAQ: EPZM) (Epizyme) at a price of $1.45 per share, to the holder in cash, without interest and less applicable withholding taxes, plus one non-transferable contingent value right (CVR) per Share, until 11:59 p.m., Eastern time on Thursday 11 August 2022, unless further extended. The tender offer was previously scheduled to expire at one minute after 11:59 p.m., Eastern time, on Monday 8 August 2022. All other terms and conditions of the tender offer remain unchanged. Each CVR represents the right to receive one or more payments in cash, of up to $1.00 per CVR, contingent upon the achievement of certain milestones upon the terms and subject to the conditions d